MBX Biosciences vs Viking Therapeutics
MBX and VKTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MBX and VKTX compare
Viking Therapeutics is the larger company, worth 1.3 times as much as MBX Biosciences ($3.4B against $2.6B).
MBX Biosciences scores higher on the StockData Score (7 against 5 for Viking Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MBX | VKTX |
|---|---|---|
| Size and price | ||
| Market cap | $2.6B | $3.4B |
| Share price | $53.12 | $26.80 |
| Change, 1 year | 121% | −31.3% |
| Change, 5 years | – | 398% |
| Beta (5Y) | 2.07 | 1.24 |
| Employees | 63 | 53 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 5.4× (better) | 5.8× |
| FCF yield | −3.9% | – |
| Profitability | ||
| Return on equity | −33.7% (better) | −96.4% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 19.58 (better) | 7.27 |
| Altman Z-score | 54.56 (better) | 2.23 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 115% | 59.4% |
| Held by insiders | 57.3% | 2.7% |
| Insider net buying, 12 months | −$2.5M (better) | −$18.2M |
| Short interest, % of float | 20.8% | 19.5% |
Go deeper
- MBX stock overview
- MBX income statement
- MBX valuation and score
- VKTX stock overview
- VKTX income statement
- VKTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.